Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?
- 1 October 2005
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 153 (4) , 701-705
- https://doi.org/10.1111/j.1365-2133.2005.06899.x
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointmentJournal of the American Academy of Dermatology, 2005
- A Multicenter Study of the Pharmacokinetics of Tacrolimus Ointment after First and Repeated Application to Children with Atopic DermatitisJournal of Investigative Dermatology, 2005
- Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccinationJournal of the American Academy of Dermatology, 2005
- Skin disorders in patients transplanted in childhoodTransplant International, 2005
- Tacrolimus ointment and skin carcinogenesis in the DMBA/TPA model in miceBritish Journal of Dermatology, 2004
- Protein oxidative damage in the stratum corneum: evidence for a link between environmental oxidants and the changing prevalence and nature of atopic dermatitis in JapanBritish Journal of Dermatology, 2003
- Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in ChildrenPediatrics, 2002
- Low Systemic Exposure after Repeated Topical Application of Pimecrolimus (Elidel®, SD Z ASM 981) in Patients with Atopic DermatitisDermatology, 2002
- Safety and Efficacy of 1 Year of Tacrolimus Ointment Monotherapy in Adults With Atopic DermatitisArchives of Dermatology, 2000
- Anti-tumor-promoting action of FK506, a potent immunosuppressive agentCarcinogenesis: Integrative Cancer Research, 1993